Dasatinib exhibits a favorable therapeutic profile in the treatment of chronic myeloid leukemia (CML) through the inhibition of BCR-ABL kinases, including c-KIT, EPH receptor kinase, PDGFRβ, and SRC family kinases, among other oncogenic kinases [82, 83]. The gene discussed is PDGFRB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.